Methylation Array Profiling as a New Clinical Diagnostic Test

染色体病理学部分的另一个里程碑是引入甲基化阵列分析，作为向CCR和外部临床社区提供的新型临床测试（根据CLIA认证，CAP认证）。建立一个全面的肿瘤分子谱将有助于最终在诊断精度和整体将影响治疗决策和治疗的结果。基于Illumina平台的甲基化阵列分析已被引入，成为现有分子诊断菜单的重要补充。基于甲基化阵列的临床测试于2019年3月开始用于中枢神经系统（CNS）肿瘤分析，作为临床研究项目的一部分，已正式报告或研究了800多例临床病例。这项工作是与NCI神经肿瘤学分支合作进行的。

Another milestone in Chromosome Pathology Section is the introduction of the Methylation Array analysis as a novel clinical test (under CLIA certification, CAP accreditation) offered to the CCR and outside clinical community. Establishing a comprehensive tumor molecular profile would assist ultimately in diagnostic precision and overall would impact the treatment decision and the outcome of the therapy. Methylation array analysis based on Illumina platform has been introduced to become an important addition to existing molecular diagnostic menu. Methylation array-based clinical testing became live for analysis of the Central Nervous System (CNS) tumor analysis in March 2019 with over 800 clinical cases been officially reported or studied as part of clinical research projects. This work is being performed in collaboration with the Neuro-Oncology Branch, NCI.